- Investor Overview
- Stock Information
- Presentations & Events
- Corporate Governance
- SEC Filings
- Investor FAQs
- Contact Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
Phone: (312) 445-2870
|View printer-friendly version|
|Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription|
SYNDROS is stocked with most of the major wholesalers for retail pharmacy ordering or through the INSYS Specialty Pharmacy Network. For more information, please call 1-844-309-3835.
SYNDROS is a liquid formulation of the pharmaceutical cannabinoid dronabinol. SYNDROS is indicated for use in treating anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (“AIDS”) and nausea and vomiting associated with chemotherapy in cancer patients who have failed to respond adequately to conventional antiemetic treatments.
“The launch of SYNDROS represents a pivotal milestone for us,” said
“SYNDROS is the first and only
About Chemotherapy Induced Nausea and Vomiting (CINV)
About Anorexia in AIDS
Since the early 1980s, there have been 1.2 million patients diagnosed in the U.S. with AIDS. Despite the advancements for the treatment of AIDS, 7-8% of AIDS patients currently experience weight loss.
SYNDROS™ Important Safety Information
SYNDROS™ may cause psychiatric and cognitive effects and impair mental and/or physical abilities. Patients with cardiac disorders may experience hypotension, hypertension, syncope, or tachycardia. Discontinue products containing disulfiram or metronidazole at least 14 days before and do not administer 7 days after treatment with SYNDROS™ (see Full Prescribing Information).
Weigh the potential risk versus benefits before prescribing SYNDROS™ to patients with a history of seizures, including those requiring anti-epileptic medication or with other factors that lower the seizure threshold. Assess risk for abuse or misuse inpatients with a history of substance abuse or dependence, prior to prescribing SYNDROS™ and monitor for the development of associated behaviors or conditions. Consider dose reduction or discontinuation, if worsening of symptoms of paradoxical nausea, vomiting, or abdominal pain worsen while on treatment.
To learn more about SYNDROS™, and its Important Safety Information, please contact
SUBSYS® and SYNDROS™ are trademarks of
This press release contains forward-looking statements including regarding our (i) belief that the launch of SYNDROS is a pivotal milestone for the Company, (ii) belief that Insys will bring additional novel therapeutic solutions to even more patients in the near future and (iii) belief that SYNDROS represents a viable alternative for the delivery of dronabinol and will fulfill a significant unmet need for both cancer patients undergoing chemotherapy who fail traditional antiemetics and AIDS patients who experience weight loss.
These forward-looking statements are based on management's expectations and assumptions as of the date of this press release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to risk factors described in our filings with the
NOTE: All trademarks and registered trademarks are the property of their respective owners.